Current characteristics associated with hereditary angioedema attacks and treatment: The home infusion based patient experience

被引:10
作者
Tachdjian, Raffi [1 ]
Banerji, Aleena [2 ]
Guyer, Autumn [2 ]
Morphew, Tricia [3 ]
机构
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Morphew Consulting LLC, Los Angeles, CA USA
关键词
C1 INHIBITOR DEFICIENCY; QUALITY-OF-LIFE; ECALLANTIDE TREATMENT; THERAPY; UPDATE; MANAGEMENT; BURDEN; RECOMMENDATIONS; EPIDEMIOLOGY; DEPRESSION;
D O I
10.2500/aap.2015.36.3832
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
This article presents a current perspective on the characteristics of hereditary angioedema (HAE) attacks and treatment as captured by a home infusion service. Retrospective data on 158 HAP patients who were enrolled in this acute treatment program were analyzed for factors surrounding an attack. The majority of patients had a high level of disease severity at baseline (88%), with a higher than expected likelihood of having a positive family history (87.8%). The most likely times for patients to call for home treatment were just before and during working hours (6:00 A.M.-5:00 P.M.). Eighty-three percent had more than one alternate mode of medication. Factors associated with a severe attack included an overall severe rating of HAP attacks in the previous year, an abdominal attack alone or a combination of peripheral and abdominal attacks versus a peripheral attack alone, and the use of two doses rather than one for treatment of the current attack. Average time to relief onset was 43.5 minutes. One dose of ecallantide was sufficient to treat the majority of attacks, and a second dose was needed in 23.6% of patients experiencing a severe attack. However, patients who reported both a severe attack rating during the previous year and experiencing only a peripheral current attack were more likely to experience a severe current attack. Acute treatment paradigms for HAP remain diverse. Understanding factors driving these decisions could help alleviate the overall burden of this disease and help overcome some of the challenges faced by the patients and their caretakers and improve their quality of life. Enhanced capture and analysis of prodromal factors in future studies should help us further alleviate the burden of this disease.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 34 条
[1]   Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond [J].
Agostoni, Angelo ;
Aygoeren-Puersuen, Emel ;
Binkley, Karen E. ;
Blanch, Alvaro ;
Bork, Konrad ;
Bouillet, Laurence ;
Bucher, Christoph ;
Castaldo, Anthony J. ;
Cicardi, Marco ;
Davis, Alvin E., III ;
De Carolis, Caterina ;
Drouet, Christian ;
Duponchel, Christiane ;
Farkas, Henriette ;
Fay, Kalman ;
Fekete, Bela ;
Fischer, Bettina ;
Fontana, Luigi ;
Fuest, George ;
Giacomelli, Roberto ;
Groener, Albrecht ;
Hack, C. Erik ;
Harmat, George ;
Jakenfelds, John ;
Juers, Mathias ;
Kalmar, Lajos ;
Kaposi, Pal N. ;
Karadi, Istvan ;
Kitzinger, Arianna ;
Kollar, Timea ;
Kreuz, Wolfhart ;
Lakatos, Peter ;
Longhurst, Hilary J. ;
Lopez-Trascasa, Margarita ;
Martinez-Saguer, Inmaculada ;
Monnier, Nicole ;
Nagy, Istvan ;
Nemeth, Eva ;
Nielsen, Erik Waage ;
Nuijens, Jan H. ;
O'Grady, Caroline ;
Pappalardo, Emanuela ;
Penna, Vincenzo ;
Perricone, Carlo ;
Perricone, Roberto ;
Rauch, Ursula ;
Roche, Olga ;
Rusicke, Eva ;
Spaeth, Peter J. ;
Szendei, George .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (03) :S51-S131
[2]   The burden of illness in patients with hereditary angioedema [J].
Banerji, Aleena .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) :329-336
[3]   Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema [J].
Bernstein, J. A. ;
Shea, E. P. ;
Koester, J. ;
Iarrobino, R. ;
Pullman, W. E. .
ALLERGY, 2012, 67 (09) :1173-1180
[4]   HAE Update: Epidemiology and burden of disease [J].
Bernstein, Jonathan A. .
ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (01) :3-6
[5]   Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency [J].
Bork, Konrad ;
Hardt, Jochen ;
Witzke, Guenther .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 130 (03) :692-697
[6]   Review of Recent Guidelines and Consensus Statements on Hereditary Angioedema Therapy with Focus on Self-Administration [J].
Cicardi, M. ;
Craig, T. J. ;
Martinez-Saguer, I. ;
Hebert, J. ;
Longhurst, H. J. .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2013, 161 :3-9
[7]   Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group [J].
Cicardi, M. ;
Bork, K. ;
Caballero, T. ;
Craig, T. ;
Li, H. H. ;
Longhurst, H. ;
Reshef, A. ;
Zuraw, B. .
ALLERGY, 2012, 67 (02) :147-157
[8]  
Craig T, 2012, WORLD ALLERGY ORGAN, V5, P182, DOI 10.1097/WOX.0b013e318279affa
[9]   Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks [J].
Craig, Timothy J. ;
Rojavin, Mikhail A. ;
Machnig, Thomas ;
Keinecke, Heinz-Otto ;
Bernstein, Jonathan A. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (03) :211-215
[10]   Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency [J].
Farkas, Henriette ;
Csuka, Dorottya ;
Veszeli, Nora ;
Zotter, Zsuzsanna ;
Szabo, Erika ;
Varga, Lilian .
ALLERGY AND ASTHMA PROCEEDINGS, 2014, 35 (03) :255-259